8Q8V image
Entry Detail
PDB ID:
8Q8V
EMDB ID:
Keywords:
Title:
Tau - CTE-MIA3
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2023-08-18
Release Date:
2023-09-20
Method Details:
Experimental Method:
Resolution:
3.80 Å
Aggregation State:
FILAMENT
Reconstruction Method:
HELICAL
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Isoform Tau-D of Microtubule-associated protein tau
Chain IDs:A, B (auth: C), C (auth: E), D (auth: B), E (auth: D), F
Chain Length:382
Number of Molecules:6
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Disease-specific tau filaments assemble via polymorphic intermediates.
Nature 625 119 125 (2024)
PMID: 38030728 DOI: 10.1038/s41586-023-06788-w

Abstact

Intermediate species in the assembly of amyloid filaments are believed to play a central role in neurodegenerative diseases and may constitute important targets for therapeutic intervention1,2. However, structural information about intermediate species has been scarce and the molecular mechanisms by which amyloids assemble remain largely unknown. Here we use time-resolved cryogenic electron microscopy to study the in vitro assembly of recombinant truncated tau (amino acid residues 297-391) into paired helical filaments of Alzheimer's disease or into filaments of chronic traumatic encephalopathy3. We report the formation of a shared first intermediate amyloid filament, with an ordered core comprising residues 302-316. Nuclear magnetic resonance indicates that the same residues adopt rigid, β-strand-like conformations in monomeric tau. At later time points, the first intermediate amyloid disappears and we observe many different intermediate amyloid filaments, with structures that depend on the reaction conditions. At the end of both assembly reactions, most intermediate amyloids disappear and filaments with the same ordered cores as those from human brains remain. Our results provide structural insights into the processes of primary and secondary nucleation of amyloid assembly, with implications for the design of new therapies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures